Mutagenesis Advance Access originally published online on January 25, 2005
Mutagenesis 2005 20(1):51-56; doi:10.1093/mutage/gei009
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Mutagenesis vol. 20 no. 1 © UK Environmental Mutagen Society 2005; all rights reserved.
The results of five coded compounds: genistein, metaproterenol, rotenone, p-anisidine and resorcinol tested in the pH 6.7 Syrian hamster embryo cell morphological transformation assay
Genetic Toxicology, GlaxoSmithKline, Park Road, Ware, Hertfordshire SG12 0DP, UK
The pH 6.7 Syrian hamster embryo (SHE) cell morphological transformation assay is a short-term in vitro test that has been used to predict rodent carcinogenicity. Previous reports have indicated that the SHE assay has an overall concordance of
80% with the 2 year rodent bioassay. We selected five compounds, genistein, metaproterenol, rotenone, p-anisidine and resorcinol, that had extensive genotoxicity and carcinogenicity data and tested them in the standard 7 day exposure SHE assay. Somewhat surprisingly, the SHE assay misclassified the actual rodent carcinogenicity of four out of the five test compounds. It is difficult to explain these findings as the actual mechanisms of SHE cell morphological transformation are currently unknown. However, it is obvious that in these studies there was no simple correlation between in vitro genotoxicity, morphological transformation in SHE cells and rodent carcinogenicity. Clearly, further research is required to accurately assess the role of the SHE assay in the carcinogenic risk assessment of new chemical entities.
* To whom correspondence should be addressed. Tel: +44 1920 883049; Fax: +44 1920 882679; Email: James.S.Harvey{at}gsk.com